Qiagen N.V.
QGENHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeQiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. Valued at $8.49B, QGEN is a mid-cap name in its sector. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories.
Market Cap
$8.49B
Beta
0.64
P/E (TTM)
21.10
P/E (Fwd)
15.69
EPS (TTM)
$1.95
EPS (Fwd)
$2.62
ROE
11.9%
ROA
6.0%
Cash
$646.3M
Total Debt
$1.67B
Free CF
$238.9M
52W Change
-14.9%
Annual Financials
Cash vs Debt
The company holds $646.3M in cash, though total debt stands at $1.67B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $238.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 11.9%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.0% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $2.14B (2022) to $2.09B (2025).
With a beta below 0.7, Qiagen N.V. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing QGEN.